A milestone moment for the Sjögren’s community! For the first time, a global Phase III trial has shown a statistically significant reduction in disease activity for Sjögren’s disease. Novartis announced that both NEPTUNUS-1 and NEPTUNUS-2 trials for ianalumab met their primary endpoint, marking an important step forward in the search for more effective treatments.
NEPTUNUS-1 evaluated the treatment given once a month, while NEPTUNUS-2 studied both monthly dosing and dosing once every three months.
Novartis plans to present the NEPTUNUS-1 and NEPTUNUS-2 data at an upcoming medical meeting and submit ianalumab, which was granted Fast Track Designation by the US Food and Drug Administration (FDA), to health authorities globally.
This progress brings hope to millions living with this complex autoimmune disease and underscores the need for continued investment in Sjögren’s research.
Read more: https://www.novartis.com/news/media-releases/novartis-announces-both-ia…
A milestone moment for the Sjögren’s community! For the first time, a global Phase III trial has shown a statistically significant reduction in disease activity for Sjögren’s disease. Novartis announced that both NEPTUNUS-1 and NEPTUNUS-2 trials for ianalumab met their primary endpoint, marking an important step forward in the search for more effective treatments.
NEPTUNUS-1 evaluated the treatment given once a month, while NEPTUNUS-2 studied both monthly dosing and dosing once every three months.
Novartis plans to present the NEPTUNUS-1 and NEPTUNUS-2 data at an upcoming medical meeting and submit ianalumab, which was granted Fast Track Designation by the US Food and Drug Administration (FDA), to health authorities globally.
This progress brings hope to millions living with this complex autoimmune disease and underscores the need for continued investment in Sjögren’s research.
Read more: https://www.novartis.com/news/media-releases/novartis-announces-both-ia…